Cardiovascular Results For Dapagliflozin Point To Sglt2 Use To Prevent Heart Failure | Latest News RSS feed

Cardiovascular Results For Dapagliflozin Point To Sglt2 Use To Prevent Heart Failure - Latest News


Fresh off new Farxiga data, AstraZeneca diabetes push points up cardiovascular, renal risks

On-screen text at the end of the ad reads: “Type 2 diabetes increases your risk of heart failure and renal disease ... clinical trial to “evaluate the effect of dapagliflozin on renal outcomes and ... read more

Pumps, Pipes, and Filters: SGLT2 Inhibitors for Most Type 2 Diabetes?

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors should be considered for use in most patients with type 2 diabetes regardless of presence of atherosclerotic cardiovascular ... of 124 to prevent ... read more

CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea

The primary composite end point was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for unstable angina, heart failure, or transient ischemic ... was established ... read more

Looking for another news?


Diabetes drug prevents heart failure

This benefit was seen across the study population, including in patients who did not have a history of heart attack or heart failure. Results of the Dapagliflozin Effect on CardiovascuLAR ... two ... read more


Diabetes medication reduces risk of heart failure hospitalization

This benefit was seen across the study population, including in patients who did not have a history of heart attack or heart failure. Results of the Dapagliflozin Effect on CardiovascuLAR ... two ... read more

What is the Best Diabetes Medication? One that Can Protect Your Heart Health

"Diabetes results in a two to four-fold increased risk of coronary heart disease and cardiovascular ... 2 (SGLT2) inhibitors and the glucose-like peptide-1 (GLP-1) agonists. Examples of SGLT-2 ... read more

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Use ... showed point estimates of effect that suggested benefit, although the individual effects did not reach significance. The results also showed that patients treated with canagliflozin had a ... read more

First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA(dapagliflozin ... important new evidence on heart failure and MACE. Heart failure is one ... read more

Cardiovascular Radiance For Jardiance

It seems likeliest that the result points to an effect common to all the SGLT2 inhibitors, but until the cardiovascular outcomes studies ... such as hospitalisation for heart failure and diabetes ... read more

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes

"We found that the benefit of dapagliflozin on heart failure ... cardiovascular events in patients with established heart disease." He also points out that the adverse effects and costs of the SGLT2 ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us